07-Mar-2002 - MediGene AG

MediGene receives US-patent regarding cervical cancer vaccine

March 6, 2001. The German-American biopharmaceutical company MediGene AG announced today that the US patent office has issued US patent No. 6,352,696. entitled "Papillomavirus truncated L1 protein and fusion protein constructs" regarding vaccines to treat tumors induced by human papilloma virus infections (HPV- infections). The patent protects specific DNA constructs used to produce the vaccine particles as well as the manufacturing process. MediGene is developing such a vaccine for the treatment of cervical cancer and its precursors, which is currently undergoing phase I/ II clinical trials. “This patent will fundamentally strengthen our position with regard to international competition. We believe it may block imitators from marketing similar HPV-vaccines“, explained MediGene’s CEO, Dr. Peter Heinrich and continued: “The consistent pursuit of our patent and licensing strategy is the basis for the development and marketing of innovative therapeutics.” Cervical carcinoma is usually associated with certain types of high risk human papilloma virus (HPV). Vaccines present a very good opportunity to treat tumor diseases and will become an important therapeutic approach in cancer therapy in the next decade according to medical forecasts.

Facts, background information, dossiers
  • HPV
  • vaccines
  • papillomaviruses
  • MediGene
  • cervical cancer
  • tumors
  • fusion proteins
  • clinical trials
  • cancer therapy
More about MediGene
  • News

    MediGene increases revenues in the first nine months significantly

    In the first nine months of 2001 the biopharmaceutical company MediGene (Neuer Markt: MDG) has successful driven forward its corporate development. Currently, MediGene has seven drug candidates in different stages of clinical development. These drug candidates were developed using diffe ... more

    Broad US-patent issued to MediGene

    The German-American biopharmaceutical company MediGene (NMarkt: MDG) announced today a significant addition to its intellectual property portfolio with the grant of US-Patent US 6,277,621. This patent gives MediGene broad protection covering the use of bacterial artificial chromosomes ( ... more


    The biopharmaceutical company MediGene AG (NMarkt: MDG) announced today the start of a phase 1/2 clinical trial for a vaccine against malignant melanoma developed together with Aventis Pharma AG. The therapeutic vaccination is based on gene transfer by so-called adeno-associated viruses ( ... more